The effect of medicinal plants on type 2 diabetes

Evaluation of Diacare (Herbal Anti diabetic drug) on hyperglycemia in diabetic patient type2: clinical trial double blind

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20210218050404N6

Enrollment

Registered

2022-03-10

Start date

2022-03-05

Completion date

Unknown

Last updated

2022-04-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 diabetes mellitus. Type 2 diabetes mellitus

Interventions

Intervention 1: Intervention group: The drug composition Diacar, based on the active ingredients in plant extracts, is taken in capsule form, in two daily doses, over a period of two months. Intervent

Eligibility

Sex/Gender

All

Age

40 Years to 60 Years

Inclusion criteria

Inclusion criteria: Diagnosis of the disease by a doctor Age from 40 to 60 years At least two years of history of type 2 diabetes Having informed and written consent to participate in the study

Exclusion criteria

Exclusion criteria: Patients with lateral infections Cardiovascular patients Pregnancy and lactation Disagreement of the physician directly responsible for the patient Food and health allergies

Design outcomes

Primary

Measure	Time frame
HBA1C change. Timepoint: Before the start of the study, 2 and 4 months after starting the drug. Method of measurement: spectrophotometer.;Fasting blood sugar. Timepoint: Before the start of the study, 2 and 4 months after starting the drug. Method of measurement: Autoanalyzer.;Metformin consumption. Timepoint: Before the start of the study, 2 and 4 months after starting the drug. Method of measurement: questionnaire.;Lipid profile test. Timepoint: Before the start of the study, 2 and 4 months after starting the drug. Method of measurement: Autoanalyzer.;Liver enzyme Aspartate aminotransferase (SGOT). Timepoint: Before the start of the study, 2 and 4 months after starting the drug. Method of measurement: Autoanalyzer.;Renal indicator Blood Urea Nitrogen (BUN). Timepoint: Before the start of the study, 2 and 4 months after starting the drug. Method of measurement: Autoanalyzer.;Renal indicator Creatinine. Timepoint: Before the start of the study, 2 and 4 months after starting the drug. Method of measurement: Autoanalyzer.;Liver enzyme Alkaline Phosphatase (ALP). Timepoint: Before the start of the study, 2 and 4 months after starting the drug. Method of measurement: Autoanalyzer.;Liver enzyme Alanine aminotransferase (SGPT). Timepoint: Before the start of the study, 2 and 4 months after starting the drug. Method of measurement: Autoanalyzer.	—

Measure

Time frame

HBA1C change. Timepoint: Before the start of the study, 2 and 4 months after starting the drug. Method of measurement: spectrophotometer.;Fasting blood sugar. Timepoint: Before the start of the study, 2 and 4 months after starting the drug. Method of measurement: Autoanalyzer.;Metformin consumption. Timepoint: Before the start of the study, 2 and 4 months after starting the drug. Method of measurement: questionnaire.;Lipid profile test. Timepoint: Before the start of the study, 2 and 4 months after starting the drug. Method of measurement: Autoanalyzer.;Liver enzyme Aspartate aminotransferase (SGOT). Timepoint: Before the start of the study, 2 and 4 months after starting the drug. Method of measurement: Autoanalyzer.;Renal indicator Blood Urea Nitrogen (BUN). Timepoint: Before the start of the study, 2 and 4 months after starting the drug. Method of measurement: Autoanalyzer.;Renal indicator Creatinine. Timepoint: Before the start of the study, 2 and 4 months after starting the drug. Method of measurement: Autoanalyzer.;Liver enzyme Alkaline Phosphatase (ALP). Timepoint: Before the start of the study, 2 and 4 months after starting the drug. Method of measurement: Autoanalyzer.;Liver enzyme Alanine aminotransferase (SGPT). Timepoint: Before the start of the study, 2 and 4 months after starting the drug. Method of measurement: Autoanalyzer.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAmin Dakhili Ardestani

Fasa University of Medical Sciences

amindakhiliardestani@yahoo.com0715335907

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026